Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €6.76 EUR
Change Today -0.047 / -0.69%
Volume 0.0
RAH On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 6:29 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by RECRO PHARMA INC (RAH) in the last 6 months

Announced 03/9/15
170.00M for Elan Holdings, Inc. and Daravita Limited
Merger/Acquisition

Recro Pharma, Inc. (NasdaqCM:REPH) agreed to acquire Alkermes Gainesville LLC and Daravita Limited from Alkermes Pharma Ireland Limited and Eagle Holdings USA, Inc. for approximately $170 million on March 7, 2015. Recro Pharma will acquire Alkermes Gainesville LLC from Eagle Holdings USA, Inc. and Daravita Limited from Alkermes Pharma Ireland Limited. The consideration will be satisfied by $50 million in cash and receipt by Alkermes Pharma Ireland of up to $120 million ...
Read More


RAH's price was unchanged after the transaction was announced on 03/9/15.
Investor / Buyer
Recro Pharma, Inc.
Creditor / Lender
Alkermes Pharma Ireland Limited
Eagle Holdings USA, Inc.
 
Announced 02/2/15
10.00M for Recro Pharma, Inc.
Private Placement

Recro Pharma, Inc. (NasdaqCM:REPH) announced that it has entered into a common stock purchase agreement with new accredited investor, Aspire Capital Fund, LLC, a fund managed by Aspire Capital Partners, LLC for gross proceeds of $10,000,000 on February 2, 2015. The term of the agreement is for a period of 24 months. As part of the transaction, the investor will purchase up to 50,000 shares or up to $500,000 per business day. The shares in the transaction will not be ...
Read More


RAH's price was unchanged after the transaction was announced on 02/2/15.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RAH:GR €6.76 EUR -0.047

RAH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RAH.
View Industry Companies
 

Industry Analysis

RAH

Industry Average

Valuation RAH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECRO PHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.